Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 151,593

Document Document Title
WO/2023/153794A1
The present invention relates to a composition for enhancing ovarian function or preventing or treating ovotoxicity. By means of Magnolia Liliflora Bud, Paeonia Lactiflora, Malt, and Astragalus Membranaceus extracts inhibiting the produc...  
WO/2023/153777A1
The present invention relates to a composition for hangover relief, the composition comprising a Cucumis melo L. extract as an active ingredient. Specifically, the Cucumis melo L. extract can mitigate an increase in blood ethanol concent...  
WO/2023/154014A1
The usage of NMDAR antagonists provides compositions and methods for treatment for the malfunctioning of the protein homeostasis network and interferes with crucial signaling pathways and is often associated with multiple human diseases....  
WO/2023/153020A1
One of the problems addressed by the present invention is to provide a cancer-cell proliferation inhibitor that contains a compound that is derived from a food component and that is highly safe. The description of the present application...  
WO/2023/153507A1
Provided are: a novel pharmaceutical composition for peritoneal disorders or peritoneal fibrosis accompanied by peritoneal inflammation; and a novel peritoneal dialysis fluid. The present invention provides a pharmaceutical composition...  
WO/2023/151513A1
The invention provides novel conjugates of tissue-binding small molecules and therapeutic agents and pharmaceutical compositions thereof, and their use in and methods of treatment of certain diseases or conditions (e.g., cancer).  
WO/2023/153479A1
A cell population which contains 75% or more of CD11b positive, F4/80 positive, CD180 positive and CD9 positive macrophages derived from a tissue selected from the group consisting of placenta, umbilical cord and amnion, and which contai...  
WO/2023/152499A1
The present invention relates to the treatment of telangiectasia, particularly telangiectasia associated with hereditary haemorrhagic telangiectasia (HHT). The present invention provides treatments for telangiectasia associated with HHT,...  
WO/2023/149227A1
[Problem] To provide a skin care composition that effectively inhibits elastase activity. [Solution] A skin care composition comprising (A) a cyclic carboxamide derivative having a specific structure or a salt of the derivative, and (B) ...  
WO/2023/149411A1
The present invention provides a pharmaceutical or food composition for animals, the composition being obtained by combining a first composition and a second composition, and being characterized in that: the first composition contains fi...  
WO/2023/149020A1
The present invention addresses the problem of providing a novel treatment agent and/or preventative agent for joint disease. The present invention provides an agent for treating and/or preventing joint disease containing, as an active i...  
WO/2023/148524A1
Adipose tissue lipoaspirated or removed from the body, containing mesenchymal stem cells, obtained with a method for promoting the anti- inflammatory properties and for improving the repairing capability, comprising a step of mechanical ...  
WO/2023/149539A1
Disclosed is a medical agent that is for treating or suppressing progression of at least one symptom selected from the group consisting of symptoms of amyotrophic lateral sclerosis and symptoms caused by amyotrophic lateral sclerosis in ...  
WO/2023/149226A1
[Problem] To provide a skin care composition that effectively inhibits tyrosinase activity. [Solution] A skin care composition comprising (A) a cyclic carboxamide derivative having a specific structure or a salt of the derivative, and (B...  
WO/2023/149450A1
The combination of a cytotoxic anticancer agent and/or a molecularly targeted drug, and a MALT1 inhibiting agent that is a compound represented by formula (I) indicated in the specification, or a salt thereof, or a co-crystal, a hydrate,...  
WO/2023/150620A1
Compositions and methods for inserting a nucleic acid encoding a polypeptide of interest into a target genomic locus in a neonatal cell, a population of neonatal cells, or a neonatal subject or for expressing a nucleic acid encoding a po...  
WO/2023/149408A1
The present invention provides a cosmetic composition, a cosmetic composition for epidermal keratinocyte proliferation, an epidermal keratinocyte proliferation agent, an antioxidant, a cosmetic composition for dermal papilla cell prolife...  
WO/2023/149443A1
The present invention relates to a pharmaceutical composition for blood cell recovery after allogeneic cord blood transplant, the pharmaceutical composition containing romiplostim as an active ingredient. The pharmaceutical composition i...  
WO/2023/149225A1
[Problem] To provide a skin care composition that effectively inhibits tyrosinase activity and elastase activity. [Solution] A skin care composition comprising (A) a cyclic carboxamide derivative having a specific structure or a salt of ...  
WO/2023/148203A1
The invention relates to a pharmaceutical composition comprising a soluble guanylate cyclase stimulator or salt thereof for use in the treatment of a medical condition comprising a chronic vascular dysfunction occurring or persisting aft...  
WO/2023/145959A1
A medicine for treating or preventing interstitial lung disease and the disease or symptoms associated with systemic scleroderma in a subject, said medicine containing, as an active ingredient, 1-\{2-[(3S,4R)-1-\{[(3R,4R)-1-cyclopentyl-3...  
WO/2023/147134A2
The present disclosure relates generally to a method of treating post-traumatic stress disorder, schizophrenia, acute stress disorder, anxiety, depression, or bone loss comprising administration of a neurokinin (NK) receptor antagonist t...  
WO/2023/143741A1
The invention relates to a new type of physiological cooling agents, coolant mixtures containing said agents, mixtures of the coolants with flavors, the use of said cooling agents, and consumer products and final preparations containing ...  
WO/2023/145804A1
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...  
WO/2023/145619A1
This non-enveloped virus inactivation composition comprises: (a) a positive ion surfactant; (b) at least one selected from (b1) aliphatic alcohols having a cLogP of 0.80-2.40 and (b2) aromatic alcohols having a cLogP of 1.4-2.0; and water.  
WO/2023/146211A1
The present invention relates to granules comprising Progerinin, capsules or sachets using same, and a preparation method therefor. More specifically, in order to develop a formulation that is advantageous when applying, to patients, Pro...  
WO/2023/145792A1
The purpose of the present invention is to provide a technique for effectively suppressing microorganism growth in a composition for oral use and the like. The present invention relates to a composition containing (A) L-ergothioneine or ...  
WO/2023/144326A1
The invention relates to a new type of physiological cooling agents, coolant mixtures containing said agents, mixtures of the coolants with flavors, the use of said cooling agents, and consumer products and final preparations containing ...  
WO/2023/146341A1
The present invention relates to: an ovarian anti-aging pharmaceutical composition comprising, as an active ingredient, a compound of chemical formula 1 or a pharmaceutically acceptable salt thereof; an ovarian anti-aging method comprisi...  
WO/2023/145530A1
This therapeutic agent for cancer contains a compound that acts on a retinoid receptor and a BRAF inhibitor. The therapeutic agent for cancer is for use alongside a BRAF inhibitor, and contains a compound that acts on a retinoid receptor...  
WO/2023/147107A1
Provided herein are antibody agents that bind specifically to Activin A, as well as compositions comprising Activin A antibody agents, and methods of making and using the same.  
WO/2023/145844A1
Provided is a substance demonstrating an anti-tumor effect by introducing changes in a tumor microenvironment (TME), including inhibition or suppression of TME formation. This invention relates to an anti-human CXCL1 antibody including d...  
WO/2023/143112A1
Disclosed are a salt form and a crystal form of an azabenzo eight-membered ring compound and an application thereof. Specifically disclosed are a crystal form A, crystal form B, crystal form C, and crystal form D of fumarate salt, hydroc...  
WO/2023/147468A1
The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including h...  
WO/2023/145833A1
Provided is a mutant MAD7 protein demonstrating enhanced breakage activity to a target site. This mutant MAD7 protein contains an amino acid sequence B resulting from mutation of an amino acid sequence A with Sequence Number 1, the amino...  
WO/2023/145812A1
The present invention provides a glycosylated protein having glucocerebrosidase activity. This glycosylated protein having glucocerebrosidase activity is obtained by adding a sugar chain having a single structure to an unglycosylated pro...  
WO/2023/140355A1
[Problem] Provided is a cancer treatment drug that suppresses the proliferation of cancer cells. [Solution] This cancer treatment drug contains a compound represented by general formula (1) or a pharmaceutically acceptable salt thereof.  
WO/2023/140524A1
The present invention relates to an antifibrotic inhibitory composition, and to: a pharmaceutical composition for preventing or treating liver fibrosis, comprising, as an active ingredient, a peptide derived from a stem cell culture solu...  
WO/2023/140350A1
The present invention provides a pharmaceutical composition for suppressing organ fibrosis, characterized by having an angiotensin II receptor antagonist as an active ingredient, and being administered at a dosage of 0.2 times or less th...  
WO/2023/139626A1
Interoception is the mechanism by which an individual is informed about the status of its own body. When interoception becomes dysfunctional, it turns into a deleterious event for the health status of an individual. The use of calcitonin...  
WO/2023/140329A1
A medicine for treating or preventing cancer, the medicine comprising a first active ingredient used together with a second active ingredient, the first active ingredient being a compound expressed by formula (1) or a salt thereof or a s...  
WO/2023/140664A1
The present invention relates to: a pharmaceutical composition for preventing or treating liver fibrosis induced by non-alcoholic steatohepatitis, containing, as an active ingredient, an expression inhibitor of lipocalin 2 or a receptor ...  
WO/2023/139581A1
Compounds represented by Formula I: (I) wherein A, B, W, V, Z, Ra, Rb, n and m are as defined in the instant specification, or by Formula la, lb, III, IV or V, as defined in the instant specification, and uses thereof in modulating an ac...  
WO/2023/140242A1
The present disclosure provides a composition for protecting a tissue isolated from a living body, said composition containing a compound of formula (I) or an ester, oxide, prodrug, pharmaceutically acceptable salt or solvate of the same.  
WO/2023/140309A1
[Problem] To elucidate the mechanism of an anti-tumor effect of a ketogenic diet therapy to discover a novel cancer treatment method. [Solution] Provided is a composition for treating cancer, the composition comprising a ketogenic diet t...  
WO/2023/140308A1
The present invention addresses the problem of providing a novel composition for the proliferation of Akkemansia muciniphila present in the intestinal flora. The composition for the proliferation of Akkemansia muciniphila contains plat...  
WO/2023/139187A1
Prodrug compounds of GLP-1/GIP receptor co-agonists are provided wherein the GLP-1/GIP receptor co-agonists have been modified by the linkage of a dipeptide to the GLP-1/GIP receptor co-agonist through an amide bond. The prodrugs disclos...  
WO/2023/136342A1
The present invention provides a cyclic peptide represented by formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, A is selected from ring-forming groups A1-A5; Xaa1 is a residue of an aromatic amino acid; Xaa2 is...  
WO/2022/136851A9
The present invention relates to the use of a reduced folate, such as 5-MTHF (5- methyltetrahydrofolate), optionally in combination with tetrahydrobiopterin (BH4) or precursors thereof, for preventing or treating disorders associated wit...  
WO/2023/136279A1
Provided are a crystal of a compound represented by formula (I) that can be used as an active pharmaceutical ingredient of a drug, salts of the compound represented by formula (I), and crystals thereof.  

Matches 401 - 450 out of 151,593